New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →
Since the arrival of personalized healthcare and molecular diagnostics, there has been growing support for utilizing DNA, RNA, and protein-based biomarker detection methods as a means to help reduce rising healthcare costs (1). Molecular diagnostics can help select the right patients for the right treatments, and define which patients require costly confirmatory diagnostic tests. In… Read article →
Do you know which pathogen is causing your patient's symptoms? With panels for 20+ pathogens causing respiratory o… https://t.co/zUpP9YxybD, Remember - reserve your spot today for the special webinar with Dr. Mairiead MacLennan on improving efficiency in t… https://t.co/AplGWYT5b2, Just one more day to register for the webinar with Dr. Mairiead MacLennan on improving efficiency in the modern mic… https://t.co/boZDQeMA9g, Visit us today at booth P3 for one more opportunity to see QIAstat-Dx and the NeuMoDx 96 in action. We look forward… https://t.co/N7OJmqnUKg, Some impressions from day1 of #ESCV2018 - visit us at booth P3 to learn about #QIAsymphony, #QIAstat-Dx and more! https://t.co/dw8ZSaJTfV, 